Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity.
Kamin F, Rommer PS, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl UK.
Abstract
Objectives:Multiple sclerosis (MS) is an autoimmune disease affecting young people and is a major cause of disability. In the course of time, disability progresses and symptoms like spasticity may occur. Spasticity is a major cost factor in MS patients. Various agents are approved for the treatment of spasticity, but each of those agents may have several side effects. Intrathecally administered steroids (triamcinolone-acetonide (TCA)) may be efficient in treating spasticity in patients with lesions in the spinal cord and no response to first-line therapeutics. The aim of this study is to show effects of TCA treatment on clinical parameters in patients with MS.
Methods:This multicentre open label study included 54 patients with MS. The clinical outcome parameters were spasticity, disability, maximum walking distance, bladder function and quality of life. All patients received physiotherapy in addition to TCA treatment to obtain optimal effects on clinical parameters.
Results:Spasticity, maximum walking distance as well as disability improved significantly (P⩽0.001) during TCA applications. Bladder function improved in every seventh patient.
Conclusion:We observed the effects of intrathecally administered TCA on different clinical parameters including bladder function. TCA administration is a safe method to treat different symptoms in MS patients. Longitudinal trials with repeated TCA cycles are needed to show long-term effects. Besides TCA treatment, physiotherapy contributes to the improvement of clinical parameters.
Source: Spinal Cord. 2014 Sep 16. doi: 10.1038/sc.2014.155 & Pubmed PMID: 25224601 (24/09/14) http://www.ms-uk.org/mssymptomsresearch
Intrathecal steroid could help spasticity
Intrathecal steroid could help spasticity
MS-UK - http://www.ms-uk.org/
-
CureOrBust
- Family Elder
- Posts: 3374
- Joined: Wed Jul 27, 2005 2:00 pm
- Location: Sydney, Australia
Re: Intrathecal steroid could help spasticity
Looks interesting, but it is "simply" a synthetic Corticosteroid. So, what would be the difference between it and IV Solu-Medrol? On the wikipedia, it says its up to 8 times more potent than prednisone. I think they would need to obe in direct comparison, as corticosteroids are already known to temporarily relieve MS symptoms.
The thing I did find interesting, is that it is available as a nasal spray (Nasacort, over the counter?), which is an area allowing more direct access to the CNS (and hence people snort illegal substances, so it would take a different "technique" when using the product). So would the spray be possibility to duplicate these results to some extent? and would they be interested in paying for research for a new income stream?
The thing I did find interesting, is that it is available as a nasal spray (Nasacort, over the counter?), which is an area allowing more direct access to the CNS (and hence people snort illegal substances, so it would take a different "technique" when using the product). So would the spray be possibility to duplicate these results to some extent? and would they be interested in paying for research for a new income stream?